How to buy Abbott Laboratories (ABT) shares in Australia

Abbott Laboratories is a medical devices business with stocks listed in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$115.59 – a decrease of 2.68% over the previous week. Here's how to invest if you're based in Australia.

Have Abbott Laboratories's shares ever split?

Abbott Laboratories's shares were split on a 10000:4798 basis on 1 January 2013. So if you had owned 4798 shares the day before the split, the next day you would own 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.

Abbott Laboratories shares at a glance

52-week range	US$99.2377 - US$121
50-day moving average more info button	US$115.8474
200-day moving average more info button	US$110.9906
Target price	US$129.8713
PE ratio more info button	35.2492
Dividend yield more info button	US$2.2 (1.89%)
Earnings per share (TTM) more info button	US$3.29

Abbott Laboratories share growth calculator

Investment amount

US$

Investment period Choose a point in time from the list 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago 2 years ago 3 years ago 5 years ago

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Abbott Laboratories price performance over time

Historical closes compared with the last close of $115.59

Compare trading platforms to buy Abbott Laboratories shares

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Abbott Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Abbott Laboratories under- or over-valued?

Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abbott Laboratories's P/E ratio

Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Abbott Laboratories shares trade at around 35x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Abbott Laboratories's PEG ratio

Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2581. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Abbott Laboratories's EBITDA

Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$10.8 billion (£8.5 billion).

The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure stock profitability.

Abbott Laboratories share price volatility

Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as US$99.2377 up to US$121. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.722. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).

Abbott Laboratories financials

Revenue TTM	US$41.2 billion
Operating margin TTM	18.75%
Gross profit TTM	US$24.6 billion
Return on assets TTM	6.49%
Return on equity TTM	14.84%
Profit margin	13.99%
Book value	22.944
Market capitalisation more info button	US$201.1 billion
EBITDA more info button	US$10.8 billion

TTM: trailing 12 months

Abbott Laboratories share dividends

Dividend payout ratio: 48.67% of net profits

Recently Abbott Laboratories has paid out, on average, around 48.67% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.89% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.89% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $2.2 per share.

While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.

Abbott Laboratories's most recent dividend payout was on 14 November 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 October 2024 (the "ex-dividend date").

Abbott Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Abbott Laboratories's total ESG risk score

Total ESG risk: 32.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 12/31/2018) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Abbott Laboratories's environmental score

Environmental score: 3.98/100

Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Abbott Laboratories's social score

Social score: 20.71/100

Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Abbott Laboratories's governance score

Governance score: 13.15/100

Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Abbott Laboratories's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Abbott Laboratories was last rated for ESG on: 2019-01-01.

Total ESG score	32.35
Total ESG percentile	60.66
Environmental score	3.98
Environmental score percentile	5
Social score	20.71
Social score percentile	5
Governance score	13.15
Governance score percentile	5
Level of controversy	3

Abbott Laboratories overview

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Frequently asked questions

• What percentage of Abbott Laboratories is owned by insiders or institutions?

  Currently 0.531% of Abbott Laboratories shares are held by insiders and 77.639% by institutions.

• When does the fiscal year end for Abbott Laboratories?

  Abbott Laboratories's fiscal year ends in December.

• Where is Abbott Laboratories based?

  Abbott Laboratories's address is: 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400

• What is Abbott Laboratories's ISIN number?

  Abbott Laboratories's international securities identification number is: US0028241000

• What is Abbott Laboratories's CUSIP number?

  Abbott Laboratories's Committee on Uniform Securities Identification Procedures number is: 002824126